Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of botulinum toxin type A (148 kDa, without complex protein) for primary blepharospasm
ChiCTR2500101763Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in idiopathic blepharospasm (BEB) (4 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Jankovic Rating Scale. Started Apr 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
idiopathic blepharospasm (BEB)
Beyond the preview
Go deeper on ChiCTR2500101763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101763.